Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Danuglipron (Pfizer) is another oral GLP-1 currently in phase 2 trials, and CT-996 (Carmot Therapeutics) is in phase 1 trials
Burgos-Morn E, Abad-Jimnez Z, Martnez de Maran A, Iannantuoni F, Escribano-Lpez I, Lpez-Domnech S, et al
Description Key Components L-Carnitine L-Tartrate, Bulking agent (Microcrystalline Cellulose, Calcium Carbonate, Maltodextrin), Anti-caking agent (Magnesium Stearate, Silicone Dioxide)
In contrast to antipsychotic agents, which predominantly alleviate positive symptoms of schizophrenia, PDE1B and PDE10A inhibitors hold promise in addressing the broader symptomatology, including the negative and cognitive symptoms that remain inadequately managed by current therapies (Sadeghi et al., 2023)
Heerspink HJ, Jongs N, Chertow GM, Langkilde AM, McMurray JJ, Correa-Rotter R, et al
The Global GLP-1 Receptor Agonist Market Size is growing at a CAGR of 6.09% from 2022 to 2032
US$ 25.42
US$ 28.15
US$ 28.14
US$ 28.63
US$ 25.06
US$ 24.61
US$ 22.18
US$ 28.38
US$ 25.43
US$ 21.27
US$ 23.69
US$ 21.82
US$ 20.25
